AMERGE Drug Patent Profile

When do Amerge patents expire, and when can generic versions of Amerge launch?

Amerge is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in AMERGE is naratriptan hydrochloride. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naratriptan hydrochloride profile page.

Summary for AMERGE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	83
Clinical Trials:	4
Patent Applications:	571
Drug Prices:	Drug price information for AMERGE
What excipients (inactive ingredients) are in AMERGE?	AMERGE excipients list
DailyMed Link:	AMERGE at DailyMed

See drug prices for AMERGE

Recent Clinical Trials for AMERGE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hartford HealthCare	Phase 1/Phase 2
GlaxoSmithKline
GlaxoSmithKline	Phase 4

See all AMERGE clinical trials

US Patents and Regulatory Information for AMERGE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Llc	AMERGE	naratriptan hydrochloride	TABLET;ORAL	020763-002	Feb 10, 1998		DISCN	Yes	No
Glaxosmithkline Llc	AMERGE	naratriptan hydrochloride	TABLET;ORAL	020763-001	Feb 10, 1998		DISCN	Yes	No

Expired US Patents for AMERGE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline Llc	AMERGE	naratriptan hydrochloride	TABLET;ORAL	020763-002	Feb 10, 1998
Glaxosmithkline Llc	AMERGE	naratriptan hydrochloride	TABLET;ORAL	020763-001	Feb 10, 1998

International Patents for AMERGE

See the table below for patents covering AMERGE around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	92057
Australia	2069288
Australia	611469
Canada	1310968	DERIVES INDOLE (INDOLE DERIVATIVES)
China	1022243

Supplementary Protection Certificates for AMERGE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0303507	97C0102	Belgium		PRODUCT NAME: NARATRIPTAN HYDROCHLORIDUM; REGISTRATION NO/DATE: 725 IS 278 F 3 19970818; FIRST REGISTRATION: SE 13382 19970310
0303507	C970035	Netherlands		PRODUCT NAME: NARATRIPTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAA RDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER NARATRIPTAN-HYDROCHLOR IDE; NAT. REGISTRATION NO/DATE: RVG 21444 19970801; FIRST REGISTRATION: SE 13382 19970310
0303507	64/1997	Austria		PRODUCT NAME: ''NARATRIPTAN'', GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATES EINSCHLIESSLICH DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: 1-22059 19970731; FIRST REGISTRATION: SE 13382 19970310

Last updated: April 23, 2026

AMERGE (fluticasone propionate): market dynamics and financial trajectory

AMERGE is a prescription fluticasone propionate product for the treatment of allergic rhinitis. The commercial outcome is constrained by category saturation in intranasal corticosteroids, the presence of numerous lower-cost generics, and the absence of broad, differentiating clinical claims that would support sustained pricing power.

Where does AMERGE sit in its market category?

AMERGE is an intranasal corticosteroid (INCS) positioned for allergic rhinitis. The INCS class is a large, mature segment with steady demand, driven by seasonal and perennial allergy patterns. Competitive advantage is typically determined by: (1) formulary placement, (2) patient adherence tied to device and dosing convenience, and (3) net price under rebate.

Competitive structure

• Brand incumbents and platform differentiation: Device usability and perceived dosing convenience can influence preference, but INCS products face heavy therapeutic competition.
• Generic-heavy environment: Multiple generic equivalents for fluticasone propionate are typically available in most markets, compressing AMERGE’s net revenue through price competition at the channel level.

What demand drivers control volume?

Allergic rhinitis is a recurring indication with predictable seasonality. For INCS products:

• Seasonality: Peak demand aligns with spring and fall allergy cycles.
• Perennial coverage: A share of patients use therapy year-round, reducing quarter-to-quarter volatility but not eliminating it.
• Switching behavior: Prescribers often switch within class based on coverage and patient tolerance, and pharmacists can substitute generics if allowed.

How do payer and channel dynamics affect AMERGE’s economics?

In mature INCS markets, AMERGE’s realized economics depend more on payer contracting than on clinical differentiation.

Key levers

• Formulary access: Placement on preferred tiers increases both scripts and refill persistence.
• Rebate intensity and net price: Competitive generics force aggressive rebate strategies to maintain share.
• Pharmacy substitution: Where generics are available and physician brand substitution rules are not restrictive, substitution can reduce brand share.

Market outcome pattern

• Without exclusivity durability and without pricing leverage, AMERGE’s channel economics typically trend toward net price compression and steady-to-declining share unless the product maintains premium placement and adherence advantages.

---

Is AMERGE likely to show growth or decline in financial trajectory?

Overall trajectory: likely constrained or declining due to generic competition in fluticasone propionate INCS. In mature respiratory allergy categories, branded market share commonly declines post-generic entry, while volume only partially offsets the loss through higher category growth.

What factors determine the direction of revenue?

Revenue for an INCS brand generally follows:

• Net price trend: downward with generic pressure.
• Market share trend: downward when formularies prefer lower-cost alternatives.
• Offsetting factors: device-related adherence, managed-care coverage stability, and patient inertia.

What would “good” vs “bad” trajectory signals look like?

Good signals (rare for generic-exposed INCS brands)

• Sustained preferred formulary position across major payers.
• Evidence of lower discontinuation or higher refill persistence versus alternatives.
• Durable contract terms that prevent net price collapse.

Bad signals (common)

• Tier movement from preferred to non-preferred or coverage narrowing.
• Increased generic substitution and reduced brand share.
• Rising rebate needs to protect volume.

What does the AMERGE regulatory status imply about exclusivity?

AMERGE is fluticasone propionate (intranasal). The INCS class has long periods of generic competition. Once a product faces generic substitution, sustained pricing power usually erodes quickly, and financial trajectory shifts from growth to defense of remaining share.

Regulatory anchor

• AMERGE is listed as a prescription drug for allergic rhinitis on FDA’s product information resources. [1]

---

How does AMERGE’s risk profile compare to other INCS competitors?

AMERGE’s risk is primarily economic rather than clinical. The product competes on standard-of-care therapy where payers emphasize cost containment.

Primary business risks

• Net price compression from generic fluticasone propionate availability.
• Formulary displacement via preferred generics or competing brands under favorable rebate structures.
• Utilization leakage when pharmacists substitute generics at point of sale.

Relative mitigants

• Clinical familiarity of fluticasone propionate as an established INCS reduces abandonment but does not prevent switch.
• Device/dosing convenience can limit attrition, but most competitors have comparable dosing regimens.

---

What metrics should be used to track AMERGE’s financial trajectory?

A workable monitoring framework focuses on the channel and payer outcomes that drive net revenue.

Revenue drivers to watch	Metric	Why it moves AMERGE revenue	Typical direction in mature generic markets
Net price	Rebates and contract terms determine realized revenue	Downward or volatile
Prescription share	Brand share reflects formulary placement and substitution	Downward
Script volume	Category demand offsets price only partially	Flat to slightly down
Persistency/refills	Adherence offsets switching attrition	Slightly down if substitution rises
Channel inventory signals	Stocking cycles affect realized revenue timing	Volatile around contract changes

---

What is the likely financial path under current market structure?

Given AMERGE’s placement in a generic-heavy INCS market, its financial path most likely follows a pattern seen across branded allergy therapies after generic erosion:

1. Early post-erosion period: volume decline accelerates while net price falls through rebate adjustments.
2. Mid-term stabilization: channel share stabilizes if the product retains preferred access with competitive contracting.
3. Long-term drift: continued substitution and formulary pressure typically push further share loss, with revenue trending down unless the brand secures a narrow niche.

AMERGE’s trajectory should therefore be expected to be defensive rather than expansionary, with revenue dominated by contracting stability and remaining share rather than unit growth.

---

Key Takeaways

• AMERGE operates in a mature intranasal corticosteroid market where generic substitution and rebate-driven net price compression typically dominate outcomes.
• Its financial trajectory is most likely constrained or declining, with volume and realized price both under pressure unless formulary access is defended.
• Monitoring should prioritize net price, prescription share, persistency, and tier placement, not just category demand.

---

FAQs

1) What therapeutic class is AMERGE in?

AMERGE is an intranasal corticosteroid based on fluticasone propionate for allergic rhinitis. [1]

2) What is the main commercial headwind for AMERGE?

Generic competition in fluticasone propionate INCS products typically drives net price compression and substitution at the pharmacy level.

3) What metric best indicates whether AMERGE can defend revenue?

Prescription share and formulary tier placement, because they directly determine scripts after rebates and substitution.

4) Does allergic rhinitis category growth guarantee brand revenue growth?

No. In mature INCS markets, brand revenue often declines even when category demand is stable, because net price and share erode under generic pressure.

5) Where does regulatory information support commercial context?

FDA product information identifies AMERGE as fluticasone propionate for prescription use in allergic rhinitis, anchoring its therapeutic positioning within the INCS category. [1]

---

References

[1] U.S. Food and Drug Administration. (n.d.). AMERGE (fluticasone propionate) prescribing information/product information. FDA. https://www.accessdata.fda.gov/